Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Innovation Council · Running

ARISE ARISE - Advanced RNA Inhalation Solutions anchored in Evolved dry powder technology.

Coordinator
RNhale GmbH, Germany
Runs
1 April 2025 to 31 March 2028
Status
Running
EU funding
€2.4m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101215031

What the project is doing

In the project's own words, from its summary on CORDIS.

One of the main challenges in the domain of respiratory RNA delivery has been administration. Today, while 15 RNA therapeutics areundergoing clinical trials for pulmonary diseases, none has yet secured regulatory approval. Our nano-embedded microparticles(NEMs) represent a disruptive approach and paradigm shift in the field of RNA therapeutics for the treatment pulmonary diseases. OurIP-protected NEM technology comprises therapeutic RNA, which is encapsulated in lipid nanoparticles (LNPs) and formulated as aninhalable dry powder.

This innovation builds the foundation to RNhale's two-pronged business concept: in-house drug developmentand RNA formulation in R&D partnerships. In brief, we have developed a standalone approach, pioneering an RNAi-based drugcandidate for the treatment of moderate and severe allergic asthma. Additionally, our scalable, and indication independentproduction technology of RNA-loaded dry powders will be a second mainstay of our commercialization strategy.

Topics

Who is involved

OrganisationCityCountryRole
RNhale GmbHPlaneggGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI